Gilead Sciences Inc(GILD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low124.14
Day High128.18
Open:125.22
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Zacks Investment Research
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
StockStory
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off
HRB
Tipranks
Analysts Offer Insights on Healthcare Companies: OrthoPediatrics (KIDS), Gilead Sciences (GILD) and Savara (SVRA)
Newswire.ca
Visionaries of the Year 2026 Honours Outstanding Community Leaders and Raises Critical Funds for Canadians Affected by Blood Cancer
Tipranks
Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
Tipranks
Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
Tipranks
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Gilead Sciences (GILD)
Tipranks
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Gilead Sciences (GILD) and Edwards Lifesciences (EW)
Tipranks
Gilead Sciences (GILD) Gets a Buy from Bernstein
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Hims & Hers Health (HIMS) and Nurix Therapeutics (NRIX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Nurix Therapeutics (NRIX) and Gilead Sciences (GILD)
Tipranks
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Hinge Health, Inc. Class A (HNGE) and MoonLake Immunotherapeutics (MLTX)
Tipranks
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Ardent Health Partners, Inc. (ARDT) and Gilead Sciences (GILD)
Tipranks
Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst
Tipranks
Scotiabank Sticks to Its Buy Rating for Gilead Sciences (GILD)
Tipranks
Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Lemaitre Vascular (LMAT) and Gilead Sciences (GILD)
Tipranks
Gilead Sciences (GILD) Receives a Buy from Citi
Tipranks
Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Gilead Sciences (GILD) and Celcuity (CELC)

Profile

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.